Clinical study supports safety, efficacy of GI Windows’ IAS as treatment option for Type 2 diabetes

GI Windows, Inc., a clinical-stage medical device company, today announced the presentation of six-month results of the first-ever clinical study evaluating the endoscopic creation of a dual-path enteral diversion using the company’s Incision-less Anastomosis System (IAS) at Digestive Disease Week® 2016 (DDW), in San Diego, Calif.

from News-Medical.Net Weight Loss News Feed http://ift.tt/1NPCy4N

Mia M.L. Bryant

Phasellus facilisis convallis metus, ut imperdiet augue auctor nec. Duis at velit id augue lobortis porta. Sed varius, enim accumsan aliquam tincidunt, tortor urna vulputate quam, eget finibus urna est in augue.

No comments:

Post a Comment